M&A Deal Summary

Nxera Pharma Acquires Heptares Therapeutics

On February 22, 2015, Nxera Pharma acquired life science company Heptares Therapeutics for 400M USD

Acquisition Highlights
  • This is Nxera Pharma’s 1st transaction in the Life Science sector.
  • This is Nxera Pharma’s largest (disclosed) transaction.
  • This is Nxera Pharma’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2015-02-22
Target Heptares Therapeutics
Sector Life Science
Buyer(s) Nxera Pharma
Deal Type Add-on Acquisition
Deal Value 400M USD
Advisor(s) Goldman Sachs (Financial)
Covington & Burling (Legal)

Target

Heptares Therapeutics

Welwyn Garden City, United Kingdom
Heptares Therapeutics Ltd. is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Its proprietary structure-based drug design technology enables us to engineer drugs for highly validated, yet historically undruggable or challenging, GPCRs.

Search 198,975 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Nxera Pharma

Tokyo, Japan
Category Company
Founded 1990
Sector Life Science
Employees350
Revenue 12.8B JPY (2023)
DESCRIPTION

Nxera Pharma is a biopharmaceutical company. Sosei’s primary business model is based on identifying novel and/or differentiated product assets or technology platforms and, through supporting these in preclinical and clinical development and establishing commercial partnerships, advancing new medicines to patients worldwide. Nxera Pharma was founded in 1990 and is based in Tokyo, Japan.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (United Kingdom) 1 of 1
Year (2015) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal